



Article

Acceptance of COVID-19 Vaccines among Adults in Lilongwe, Malawi: A Cross-Sectional Study Based on the Health Belief Model

Qun Ao ¹, Robert Okia Egolet ², Hui Yin ^{1,3,*} and Fuqiang Cui ^{1,3}

- Department of Global Health, School of Public Health, Peking University, Beijing 100191, China; aoqun2018@gmail.com (Q.A.); cuifuq@bjmu.edu.cn (F.C.)
- Global Health Collaborating Centre for Research and Training in Health Sciences, Peking University, P.O. Box 166, Lilongwe 265, Malawi; egoletroberts@gmail.com
- Institute for Global Health and Development, Peking University, Beijing 100191, China
- * Correspondence: yinhui@pku.edu.cn

Abstract: The COVID-19 pandemic has had a significant economic and social impact on Malawi. Promoting vaccination is a key protection measure against COVID-19. Employing the health beliefs model (HBM), this study explores various factors that influence COVID-19 vaccination acceptance (intentions and behavior) among adult residents of Malawi. A semi-structured questionnaire was used for data collection. A field-based survey was conducted among adult residents in Lilongwe, Malawi. Descriptive statistics, linear regression, the Chi-square test, and Pearson's correlation statistics were used for data analysis. A total of 758 questionnaires were involved. Respondents aged 18-24 (OR = 5.079, 95% CI 2.303-11.202), 25-34 (OR = 2.723, 95% CI 1.363-5.438), urban residents (OR = 1.915, 95% CI 1.151-3.187), graduates/professionals (OR = 1.193, 95% CI 0.857-1.651), health workers (OR = 4.080, 95% CI 1.387-12.000), perceived susceptibility (OR = 1.787, 95% CI 1.226-2.605), perceived benefit (OR = 2.992, 95% CI 1.851-4.834), and action cues (OR = 2.001, 95% CI 1.285-3.115) were predictors for "acceptance of COVID-19 vaccine". The health belief model structure can be used as a good predictor of vaccine acceptance, especially "perceived susceptibility," "perceived benefit," and "action cues". Strengthening COVID-19 vaccine education in these areas will be an important future intervention.

Keywords: vaccine acceptance; COVID-19 vaccine; health beliefs model; intention; behavior



Citation: Ao, Q.; Egolet, R.O.; Yin, H.; Cui, F. Acceptance of COVID-19 Vaccines among Adults in Lilongwe, Malawi: A Cross-Sectional Study Based on the Health Belief Model. Vaccines 2022, 10, 760. https:// doi.org/10.3390/vaccines10050760

Academic Editors: Annalisa Rosso, Azzurra Massimi, Gianluca Voglino and Maria Rosaria Gualano

Received: 12 April 2022 Accepted: 9 May 2022 Published: 11 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

The COVID-19 pandemic has triggered an unprecedented and rapid global public health crisis. As one of the most pressing global threats, the pandemic has affected all aspects of life around the world. Countries have implemented strict precautions and controls to contain the outbreak of COVID-19, such as travel bans and lockdowns [1]. However, new variants, such as Delta and Omicron, are making it harder to contain the epidemic. The development and deployment of vaccines is recognized as one of the most promising health intervention strategies and an important new tool in the fight against COVID-19 [2]. Adequate vaccination coverage can help to reduce infection rates and subsequent mortality from COVID-19. To achieve the goal of containing COVID-19 and returning to normal life, countries need to vaccinate at least 70% of the population in order to build herd immunity against COVID-19. Malawi is a low-income country where public health services are challenged [3]. Controlling the COVID-19 pandemic and conducting vaccination campaigns remain huge challenges for Malawi.

As of 4 December 2021, 1,501,147 vaccine doses have been administered in Malawi. 878,471 and 340,249 people have received the first and second doses of the AstraZeneca vaccine, respectively, while 282,427 people have received a full dose of the Johnson &

Vaccines 2022, 10, 760 2 of 21

Johnson vaccine, bringing the total number of fully vaccinated people to 622,676. Malawi currently plans to vaccinate 10.97 million people (60% of the population).

Apart from the scarcity and logistical issues of candidate vaccines, vaccination hesitancy is one of the most critical barriers to achieving mass COVID-19 vaccination rates. According to the World Health Organization, vaccine hesitancy is a significant barrier as "even when a COVID-19 vaccine is available, it can be rejected for a variety of reasons." Reluctance or refusal to vaccinate threatens progress in tackling vaccine-preventable diseases, and vaccine hesitancy is one of the world's top-10 public health problems. Several factors may influence the acceptance or hesitancy of the COVID-19 vaccine [4]. Previous studies (conducted in the US, UK, Australia, Japan, Nigeria, and other countries) [1,5–13] have shown that reduced willingness to vaccinate is associated with females, lower socioe-conomic status, unemployment, and less educated respondents. In addition, distrust of vaccines, concerns about unforeseen side effects in the future, and negative discussions about vaccines on social media may also cause people to hesitate about whether to get vaccinated [14,15].

The health belief model (HBM) is a conceptual framework widely used to study health beliefs that explain, predict, and influence behavior. HBM advises people to weigh the severity of the health threat they face (for example, perceived susceptibility and severity) against the perceived benefit or harm of taking a particular action related to that health threat (for example, vaccination) (Figure 1). Their risk assessment can be influenced by various factors, including action cues from trusted information sources and the social context in which they live and with which they interact. These factors have long been considered essential predictors of influenza vaccine uptake, and emerging studies suggest that they may also be necessary for COVID-19 vaccine uptake [16–19].




Figure 1. Conceptual framework of the determinants of COVID-19 vaccine acceptance (based on HBM).

There is a real need for more research into the perceptions and acceptance of COVID-19 vaccines among Malawian residents, especially as the government is committed to a mass COVID-19 vaccination program. The purpose of this study was to investigate current vaccination rates for COVID-19 among Malawians, assess the level of COVID-19 vaccine hesitancy among Malawians, and explore the factors influencing vaccination and willingness to be vaccinated against COVID-19. The results of this study have important implications for the health sector when developing best practices for implementing COVID-19 vaccination programs, helping healthcare providers and policymakers to plan targeted education campaigns and vaccination awareness campaigns.

Vaccines 2022, 10, 760 3 of 21

2. Materials and Methods

2.1. Study Design and Data

A cross-sectional design was used for this survey. The fieldwork was conducted in Lilongwe, Malawi, by the Peking University Research and Training Centre in Malawi (PKURTC) from 19 November to 30 November 2021. The target population were adults (aged 18 and above) living in Lilongwe, Malawi. Participants who had difficulties in communication and those who did not consent to the survey were excluded. A sample size of 693 was recommended, with an assumption of a 95% confidence interval (CI) regarding a 5% margin of error and a response rate of 60%. Participation was voluntary and came with no award, and all responses were anonymous. The final sample exceeded this estimate. A total of 758 questionnaires were collected and used for the analysis.

The study adopted a two-stage sampling technique consisting of the selection of residential areas and individuals. For the primary sampling unit, we used simple cluster sampling based on the list of Lilongwe's administrative divisions (58 areas in total). As a result, 15 areas were selected from the list. Within each selected area, the sample sizes were population-weighted. We used systematic sampling of households according to house numbers and household heads in the survey.

A semi-structured questionnaire was used for the data collection. The questionnaire was deliberate, and some surveys regarding COVID-19 vaccination were conducted in other countries and reviewed by experts. It was initially prepared in English and then translated into Chichewa (see online Appendix A). The questionnaire was digitalized and programmed on tablets using Open Data Kit (ODK) software, version 1.28.4 (https://forum.getodk.org/ accessed on 11 April 2022). Investigators were assigned to each area and captured individual-level quantifiable indicators face to face.

The survey consisted of three sections: (1) general information and health status, including gender, age, education, residence, occupation, marital status, economic status, chronic disease, and history of vaccine rejection; (2) the health belief model, including two items on perceived susceptibility to COVID-19, two items on perceived severity, two items on the perceived benefits of getting vaccinated against COVID-19, one item on perceived barriers, and four items on action cues; (3) acceptance (intention and behavior) of the COVID-19 vaccine.

2.2. Measures

The dependent variable in this study was the acceptance of the COVID-19 vaccine, which was split into two parts: (1) behavior—taking the COVID-19 vaccine, and (2) intention—willing to get vaccinated, but has not yet received a vaccine. The rest were defined as vaccine unacceptance (had not taken or refused to take the COVID-19 vaccine). Therefore, the outcome variables were assessed with two items: "Have you taken a COVID-19 vaccine?" and "Would you accept or refuse a COVID-19 vaccine if it were offered to you?".

We constructed independent variables based on the health belief model, including perceived susceptibility, perceived severity, perceived barriers, perceived benefits, action cues, and background factors (sociodemographic and disease history) of the HBM model. Each section consisted of several items, each item was answered yes/no, and each item was individually included in the regression analysis.

2.3. Statistical Analysis

Statistical analyses were performed in SPSS 25. Descriptive statistical analyses were used to characterize the study population. Correlation coefficients were calculated using $\chi 2$ to determine the association between the selected possible predictors and vaccination status or willingness to vaccinate. Those independent variables found to be statistically significant were included in the logistic regression model. A two-sided p-value of <0.05 was considered statistically significant. The final model was presented with adjusted odds ratios (OR), 95% confidence intervals (CI), and corresponding p-values.

Vaccines 2022, 10, 760 4 of 21

Consent was sought from Lilongwe's residents for participation before the questionnaire began. The study was designed and conducted according to the ethical principles established by Peking University. The National Committee on Research in the Social Sciences and Humanities, of The National Commission for Science and Technology, approved this study (P.08/21/593).

3. Results

A total of 758 people were included in the analysis, of which 189 (24.9%) were vaccinated, a further 271 (35.8%) were willing to be vaccinated but had not yet received the vaccine, and 298 (39.3%) refused to be vaccinated. The characteristics of the samples are shown in Tables 1 and 2.

Table 1. Demographic characteristics and *p*-values of the samples.

Variables	Total l	N = 758		Vaccine	Acceptance N	= 460	Unacc	cine eptance = 189	<i>p</i> -Value
				nated	but not yet be	e vaccinated een vaccinated			
		0/		: 189		: 271		0/	
	n	%	n	%	n	%	п	%	
			Sociode	mograph	ic characteristic	es .			
Gender									0.012 *
Male	260	34.3	80	30.8	93	35.8	87	33.5	
Female	498	65.7	109	21.9	178	35.7	211	42.4	
Age									<0.001 *
18–24	173	22.8	23	13.3	63	36.4	87	50.3	
25–34	263	34.7	62	23.6	101	38.4	100	38	
35–44	162	21.4	55	34	49	30.2	58	35.8	
45–54	80	10.6	21	26.3	31	38.8	28	35	
55 and above	80	10.6	28	35	27	33.8	25	31.3	
Residence									<0.001 *
Urban	246	32.5	98	39.8	66	26.8	82	33.3	
Rural	512	67.5	91	17.8	205	40	216	42.2	
Religion									0.275
Christian	679	89.6	174	25.6	240	35.3	265	39	
Islam	35	4.6	10	28.6	11	31.4	14	40	
Other(African traditional religion/Chewa/None)	44	5.8	5	11.4	20	45.5	19	43.2	
Marital status									0.089
Married	549	72.4	126	23	191	34.8	232	42.3	
Never married	114	15	32	28.1	41	36	41	36	
Divorced	58	7.7	17	29.3	25	43.1	16	27.6	
Widowed	37	4.9	14	37.8	14	37.8	9	24.3	
Education									<0.001 *
No high school	360	47.5	59	16.4	150	41.7	151	41.9	
High school	214	28.2	58	27.1	68	31.8	88	41.1	
College	64	8.4	31	48.4	16	25	17	26.6	
Graduate/Professional	30	4	21	70	3	10	6	20	
Not educated	90	11.9	20	22.2	34	37.8	36	40	

Vaccines **2022**, *10*, *7*60 5 of 21

 Table 1. Cont.

Variables	Total I	N = 758		Vaccine A	cceptance N	= 460	Unacce	cine eptance 189	<i>p-</i> Value
Employment									<0.001 *
Government employee	27	3.6	20	74.1	1	3.7	6	22.2	
Nongovernment employee	70	9.2	26	37.1	22	31.4	22	31.4	
Self-employed	197	26	56	28.4	61	31	80	40.6	
Student	18	2.4	5	27.8	9	50	4	22.2	
Retired	7	0.9	5	71.4	1	14.3	1	14.3	
Unemployed	288	38	51	17.7	102	35.4	135	46.9	
Other	151	19.9	26	17.2	75	49.7	50	33.1	
Healthcare worker									<0.001 *
Yes	27	3.6	21	77.8	2	7.4	4	14.8	
No	731	96.4	168	23	269	36.8	294	40.2	
Monthly income(MWK)									<0.001 *
0–25,000	502	66.2	144	28.7	230	45.8	128	25.5	
25,000-50,000	98	12.9	21	21.4	26	26.5	51	52	
50,000 and above	158	20.8	24	15.2	15	9.5	119	39.3	
			Н	lealth chara	cteristics				
Chronic disease									0.380
Yes	156	20.6	44	28.2	49	31.4	63	40.4	
No	602	79.4	145	24.1	222	36.9	235	39	
Self-reported health									0.065
Good	535	70.6	129	24.1	205	38.3	201	37.6	
Fair	201	26.5	51	25.4	59	29.4	91	45.3	
Poor	22	2.9	9	40.9	7	31.8	6	27.3	
Ever diagnosed with COVID-19									0.015 *
Yes	34	4.5	15	44.1	12	35.3	7	20.6	
No	724	95.5	174	24	259	35.8	291	40.2	
Historic vaccine rejection									<0.001 *
Yes	159	21	13	8.2	43	27	103	64.8	
No	599	79	176	29.4	228	38.1	195	32.6	

^{*} p < 0.05.

Table 2. Health benefit model characteristics and p-values of the samples.

Variables	Total 1	Total N = 758 Vaccine Acceptance N = 460 Unacceptance N = 189			Vaccine Acceptance N = 460		eptance	<i>p</i> -Value	
				nated	not yet been	vaccinated but n vaccinated	8	7	
			N =	: 189	N =	= 271			
	n	%	n	%	n	%	n	%	
			P	erceived susc	ceptibility to COV	'ID-19			
			Do you ag	ree that COV	ID-19 is contagio	us?			<0.001 *
Agree	658	86.8	181	27.5	248	37.7	229	34.8	
Disagree	100	13.2	8	8	23	23	69	69	
		Do you t	hink getting	COVID-19 is	currently a possi	bility for you?			<0.001 *
Agree	594	78.4	157	26.4	240	40.4	197	33.2	
Disagree	164	21.6	32	19.5	31	18.9	101	61.6	

Vaccines 2022, 10, 760 6 of 21

Table 2. Cont.

Variables	Total N	I = 758		Vaccine Ac	ceptance N = 46	60	Vace Unacce N =	ptance	<i>p-</i> Value
				Perceived sev	erity of COVID) -19			
	Do	vou agree t	hat the COV	TD-19 pandem	ic poses a risk t	o people in Mala	wi?		<0.001 *
Agree	698	92.1	186	26.6	259	37.1	253	36.2	
Disagree	60	7.9	3	5	12	20	45	75	
Do v	ou agree th	at the conse	equences of s	getting COVID	-19 can be serio	ous and could eve	en lead to dea	th?	<0.001 *
Agree	697	92	188	27	257	36.9	252	36.2	
Disagree	61	8	1	1.6	14	23	46	75.4	
			Perceived be	enefits of gettir	ng vaccinated as	gainst COVID-19			
Do you agree that a COVID-19 vaccine can decrease your chances of contracting COVID-19 or suffering from complications?							<0.001 *		
Agree	615	81.1	177	28.8	239	38.9	199	32.4	
Disagree	143	18.9	12	8.4	32	22.4	99	69.2	
Do you agree that a COVID-19 vaccine can stop the virus from spreading within communities and between countries?							countries?	<0.001 *	
Agree	615	81.1	178	28.9	233	37.9	204	33.2	
Disagree	143	18.9	11	7.7	38	26.6	94	65.7	
			Perceived ba	arriers to gettir	ng vaccinated as	gainst COVID-19			
	Do	you agree t	that immuni:	zation requirer	nents go agains	t freedom of choi	ice?		0.064
Agree	578	76.3	146	25.3	194	33.6	238	41.2	
Disagree	180	23.7	43	23.9	77	42.8	60	33.3	
				Ac	tion cues				
		Do you	ı know some	eone who has b	een infected by	COVID-19?			<0.001 *
Yes	267	35.2	107	40.1	75	28.1	85	31.8	
No	491	64.8	82	16.7	196	39.9	213	43.4	
	На	ve you rece	eived inform	ation about CC	OVID-19 and va	ccines from friend	ds?		0.001 *
Yes	472	62.3	133	28.2	149	31.6	190	40.3	
No	286	37.7	56	19.6	122	42.7	108	37.8	
			nformation a		9 and vaccines	from healthcare p	providers?		0.791
Yes	45	5.9	14	31.1	17	37.8	14	31.1	
No	713	94.1	175	24.5	254	35.6	284	39.8	
	Hav					cines from the ra			0.042 *
Yes	385	50.8	106	27.5	123	31.9	156	40.5	
No	373	49.2	83	22.3	148	39.7	142	38.1	

^{*} *p* < 0.05.

3.1. Sample Characteristics of Two Independent Classification Variables

3.1.1. Demographic Characteristics

The study subjects comprised 498 (65.7%) females and 679 (89.6%) Christians. Most respondents were married (72.4%) and from rural areas (67.4%). One-third of the study participants were 25–34 years old. Among the respondents, 87.6% had a high school education level or below, while 11.9% had no education. Regarding their occupations, 38% had no job, while 3.6% of the respondents were healthcare workers. One-third of the study participants were in the lowest income category. In terms of health status, most of the population did not have any chronic diseases (79.4%), and only 2.9% considered themselves to be in poor health. A total of 4.5% of the participants reported having had COVID-19 before, while 21% had refused a vaccine recommended by a physician due to doubts.

As seen in Table 1, there were significant differences in COVID-19 vaccine acceptance among people of a different gender, age, education, occupation (health worker), monthly income, urban/rural residence, history of COVID-19 infection, and history of vaccine refusal. Table 2 also reflects a significant difference in COVID-19 vaccine acceptance among

Vaccines 2022, 10, 760 7 of 21

people with different attitudes toward the various components of the health belief model (perceived susceptibility, severity, benefits, barriers, and action cues).

3.1.2. Health Benefit Model Characteristics

The majority of respondents agreed on the susceptibility, severity, and benefits of COVID-19 (more than 80%), with 86.8% agreeing that COVID-19 is contagious and 78.4% believing that they are likely to get it. About 92% of participants considered the consequences of COVID-19 to be serious, while 81.1% thought it would be beneficial to be vaccinated against COVID-19 to decrease the chance of contracting COVID-19 or suffering complications and in order to stop the spread of the virus in the community. A total of 76.3% perceived a barrier that prevented them from getting vaccinated. As for the action cues, 35.2% knew someone who had been infected. The majority (62.3%) heard information about vaccines from friends, and nearly half obtained information from the radio, while only 5.9% obtained it from healthcare providers. The results are shown in Table 2.

3.2. Influencing Factors Associated with the Acceptance of the COVID-19 Vaccine

The influencing factors for the acceptance of the COVID-19 vaccine are shown in columns 2–3 of Table 3. A Chi-square analysis of the sociodemographic and health-related variables revealed some significant variables. When entered into a binary logistic regression model, these variables were associated with "acceptance of COVID-19 vaccine". In the final model, respondents aged 18–24 (OR = 5.079, 95% CI 2.303–11.202), 25–34 (OR = 2.723, 95% CI 1.363–5.438), urban residents (OR = 1.915, 95% CI 1.151–3.187), graduates/professionals (OR = 1.193, 95% CI 0.857–1.651), health workers (OR = 4.080, 95% CI 1.387–12.000), self-reporting health as good (OR = 4.08, 95% CI 1.410–11.840) and fair (OR = 3.145, 95% CI 1.063–9.308), perceived susceptibility (COVID-19 is contagious for you (OR = 1.787, 95% CI 1.226–2.605)), perceived benefit (agree that the vaccine could stop the spread of COVID-19 (OR = 2.992, 95% CI 1.851–4.834)), and action cues (know someone who has been infected by COVID-19 (OR = 2.001, 95% CI 1.285–3.115)) were predictors for the "acceptance of the COVID-19 vaccine". Meanwhile, the historic rejection of vaccines (OR = 0.160, 95% CI 0.083–0.309) was an inhibitor of the "acceptance of the COVID-19 vaccine".

Table 3. Outcomes of logistic regression (ref: Vaccine unacceptance).

Variables	Binary Logistic	Regression]	Multinomial Lo	gistic Regression	
	Acceptance of Vacci		Vaccin	ated	Willing to Be Vaccinated but Not Yet Been Vaccinated	
	aOR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value
		Demog	raphic characteristics	S		
Age						
18–24	5.079 (2.303–11.202)	<0.001 *	1.181 (0.989–1.546)	0.001 *	1.46 (0.621–1.725)	0.386
25–34	2.723 (1.363–5.438)	0.005 *	1.391 (0.835–1.684)	0.044 *	0.898 (0.396–2.038)	0.798
35–44	1.057 (0.537–2.079)	0.872	0.83 (0.372–1.851)	0.65	1.058 (0.450–2.487)	0.898
45–54	1.802 (0.815–3.985)	0.146	0.584 (0.237–1.440)	0.243	0.924 (0.355–2.406)	0.872
55 and above	1		1		1	
Residence						
Urban	1.915 (1.151–3.187)	0.012 *	1.667 (0.868–3.201)	0.025 *	0.626 (0.341–1.149)	0.131
Rural	1		1		1	

Vaccines **2022**, *10*, *7*60 8 of 21

Table 3. Cont.

Binary Logistic	Regression	Multinomial Logistic Regression				
		Vaccina	ited			
aOR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p-</i> Value	
1.634 (0.849–3.137)	0.141	0.669 (0.302–1.483)	0.322	0.959 (0.491–1.873)	0.902	
(0.475-2.080)	0.986	(0.397-2.376)	0.950	(0.571-2.733)	0.577	
(0.254-1.733)	0.403	(0.442-5.057)	0.519	(0.300-2.996)	0.928	
(0.857-1.651)	0.008 *	(0.940-20.044)	0.040 *	(0.317 - 10.644)	0.502	
		1		1		
orker 4.080		2.262		0.227		
(1.387–12.000)	0.011 *	(0.602-8.910)	0.002 *	(0.034-1.646)	0.133	
1.982	0.060	3.845	<0.000 *	11.604	<0.000 *	
1		1		(6.260–21.369)		
	Health sta	itus and vaccine histo	ory			
ealth						
(1.410-11.840)	0.01 *	(0.098-1.577)	0.188	(0.377-5.677)	0.576	
(1.063-9.308)	0.038 *	(0.081-1.320)	0.116	(0.186–2.925)	0.665	
		1		1		
		0.120		0.492		
(0.083 - 0.309)	<0.001 *	(0.057 - 0.250)	<0.000 *	(0.291 - 0.798)	0.005 *	
1				1		
	НВ	M characteristics				
	Perce	eived susceptibility				
	ou	2 042		0.500		
	0.003 *		0.013 *		0.002 *	
1		1		1		
		Perceived severity				
COV	/ID-19 can be se	erious and can even l	ead to death			
				0,925	0.615	
(0.904–4.113)	0.087	(1.049–95.575)	0.045 *	(0.370–2.316)	0.868	
1		1		1		
	Pe	erceived benefits				
	op the virus fro		communities ar			
2.992	0.004.4	2.876	0.020 *	2.450	0.000 *	
(1.851–4.834)	<0.001 *	(1.057 - 7.829)	0.039 *	(1.096-5.474)	0.029 *	
	Acceptance of Vaccin aOR (95% CI) 1.634 (0.849–3.137) 0.994 (0.475–2.080) 0.664 (0.254–1.733) 1.193 (0.857–1.651) 1 orker 4.080 (1.387–12.000) 1 (MWK) 1.982 (0.991–4.030) 1 ealth 4.08 (1.410–11.840) 3.145 (1.063–9.308) 1 ejection 0.160 (0.083–0.309) 1 COV 2.137 (0.904–4.113) 1	1.634 (0.849–3.137) 0.994 (0.475–2.080) 0.664 (0.254–1.733) 1.193 (0.857–1.651) 1 orker 4.080 (1.387–12.000) 1 (MWK) 1.982 (0.991–4.030) 1 Health statealth 4.08 (1.410–11.840) 3.145 (1.063–9.308) 1 ejection 0.160 (0.083–0.309) 1 HB Perce s contagious for you 1.787 (1.226–2.605) 1 COVID-19 can be see 2.137 (0.904–4.113) 1 Perce 19 vaccine can stop the virus fro	Acceptance of COVID-19 Vaccine aOR (95% CI) 1.634 (0.849-3.137) 0.994 (0.994 (0.475-2.080) 0.664 (0.254-1.733) 1.193 (0.857-1.651) 1 0.088* 4.080 (1.387-12.000) 1 (MWK) 1.982 (0.991-4.030) 1 Health status and vaccine historealth 4.08 (1.410-11.840) 3.145 (1.063-9.308) 1 ejection 0.160 (0.083-0.309) 0.080 eject	Acceptance of COVID-19 Vaccine aOR (95% CI) p-Value OR (95% CI) p-Value 0.669 (0.349-3.137) 0.994 (0.475-2.080) 0.664 (0.254-1.733) 1.193 (0.857-1.651) 1 0.008 * 4.342 (0.849-3.120) 1 1 0.008 * 4.342 (0.940-20.044) 1 1 0.0094-20.044) 1 1 0.000 * 3.845 (0.991-4.030) 1 1 1 1 Health status and vaccine history ealth 4.08 (1.410-11.840) 3.145 (1.063-9.308) 1 1 HBM characteristics Perceived susceptibility 5 contagious for you 1.787 (1.226-2.605) 1 1 Perceived serious and can even lead to death 2.137 (0.904-4.113) 0.087 9.959 (1.049-95.575) 1 P-Value OR (95% CI) p-Value OR (95% CI) p-Value P-Value P-Value OR (95% CI) p-Value P-Value OR (95% CI) p-Value P-Value OR (95% CI) p-Value 0.322 (0.327-1.483) 0.040 * 0.040 * 0.040 * 0.000 * 0.0	Acceptance of COVID-19 Vaccine aOR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) 0.634 (0.849-3.137) 0.141 0.669 0.972 (0.491-1.873) 0.994 (0.475-2.080) 0.664 (0.254-1.733) 0.403 0.1508 0.664 (0.254-1.733) 0.008 * 0.0972 (0.492-2.076) 0.664 (0.254-1.733) 0.008 * 0.008 * 0.940-20.044) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

Vaccines **2022**, 10, 760 9 of 21

Variables	Binary Logistic	Regression	Multinomial Logistic Regression				
	-	Acceptance of COVID-19 Vaccine		ated	Willing to Be Vaccinated b Not Yet Been Vaccinated		
	aOR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value	
			Action cues				
Known sor	neone infected by CO	VID-19					
V	2.001	0.002 *	2.022	0.011 *	0.965	0.007	

(1.174 - 3.480)

1

Table 3. Cont.

(1.285 - 3.115)

1

Yes

No

0.002 *

Abbreviations: OR = odds ratio; aOR = adjusted odds ratio; CI = confidence interval. * p-values < 0.05 were considered statistically significant.

0.011 *

0.887

(0.587 - 1.584)

1

3.3. Influencing Factors Associated with Positive Vaccination Intention and Behavior

According to the Chi-square calculation, it can be seen in Tables 1 and 2 that positive vaccination intention and behavior are statistically correlated with gender, age, urban residents, education, employment, healthcare worker, monthly income, previous diagnosis of COVID-19, historic vaccine rejection, perceived susceptibility to COVID-19, perceived severity of COVID-19, perceived benefits and barrier to getting a COVID-19 vaccine, and action cues. Therefore, in a multinomial regression analysis, we only consider these significantly correlated variables as predictive variables.

As shown in columns 4–5 of Table 3, multinomial logistic regressions found that the promoters of vaccination behavior (Vaccinated) included age 18-24 (OR = 1.118, 95% CI 0.989-1.546), age 25-34 (OR = 1.391, 95% CI 0.853-1.684), urban residents (OR = 1.667, 95% CI 0.868-3.201), monthly income (0–50,000 MWK) (OR = 3.845, 95% CI 2.068-7.148), graduate/professional (OR = 4.343, 95% CI 0.940-20.044), healthcare worker (OR = 2.362, 95% CI 0.068-8.910), perceived susceptibility (COVID-19 is contagious for you) (OR = 1.285, 95% CI 1.147-1.554), perceived severity (OR = 9.959, 95% CI 1.049-95.575), perceived benefit (COVID-19 vaccine can stop the virus from spreading in communities and countries (OR = 2.876, 95% CI 1.057-7.829)), and action cues (know someone who has been infected by COVID-19 (OR = 2.022, 95% CI 1.174-3.480)).

According to columns 6–7 of Table 3, the promoters of vaccination intention (Willing to be vaccinated but not yet) included monthly income (0–50,000 MWK) (OR = 11.604, 95% CI 6.260–21.509), perceived susceptibility (COVID-19 is contagious for you) (OR = 2.532, 95% CI 1.423–4.505), and perceived benefit (COVID-19 vaccine can stop the virus from spreading in communities and countries (OR = 2.450, 95% CI 1.096–5.474)).

The rejection of a historic vaccine (OR = 0.12, v95% CI 0.057–0.250) (OR = 0.482, v95% CI 0.291–0.798) is an inhibitor of vaccination behavior and intention.

4. Discussion

This study explores the predictors of intention and behavior as they pertain to COVID-19 vaccines among adults in Lilongwe, Malawi, and the applicability of the health beliefs model. There are only previous studies about Malawian residents' knowledge, attitudes, and practices regarding COVID-19 [3] and Malawian healthcare workers' vaccination status [20].

This study shows that perceived susceptibility and perceived benefit in the HB8M model are essential factors for promoting COVID-19 vaccine acceptance, improving people's vaccination intention, and promoting people's vaccination behavior. Perceived severity and crucial action cues such as knowing someone who has had COVID-19 can improve vaccination acceptance by promoting vaccination behavior. Perceived impairment did not play a role in this study. Consistent with previous research [21–23], the main dimensions of the HBM model were almost all related to COVID-19 vaccine acceptance. However, our

Vaccines 2022, 10, 760 10 of 21

study distinguished between the different facilitation effects of different dimensions on vaccination intention and behavior.

In addition, as background factors that may be involved in vaccination decision making in the HBM model, we also analyzed their potential influence on vaccination intention and behavior. In the current study, those aged between 18 and 34, graduates/professionals, and healthcare workers had more active vaccination behavior. The high acceptance of the COVID-19 vaccine among healthcare workers is consistent with another study on COVID-19 vaccination among healthcare workers in Malawi [20]. Likewise, other studies have found that young people and those with higher education levels are more likely to be vaccinated [24,25]. We presume that this is possibly because they were given more information about vaccines and were better able to make informed decisions. In addition, people with lower monthly incomes have a higher acceptance of the COVID-19 vaccine, which is consistent with some previous studies [26–28]. This is widely believed to be due to the government's policy of free vaccines.

According to the results of this study, the most widely available sources of information about COVID-19 vaccines are the radio and friends. There is little information from doctors and a lot of ignorance or incorrect knowledge about vaccines, which has led to distrust and the rejection of COVID-19 vaccines among Malawians [29]. Therefore, Malawi should be supported in its vaccination outreach and community mobilization campaigns to raise awareness of COVID-19 through radio programs, jingles, and volunteer door-to-door outreach services [30]. The education of the population should be strengthened regarding their vulnerability to COVID-19 infection. People need to be aware of existing health risks, feel at risk, and take protective measures. The benefits of vaccination also need to be highlighted. People need to be aware that vaccines protect them and their communities. Additionally, we can spread information on real-life COVID-19 cases and successful vaccination stories to promote vaccination behavior. We should also track and address rumors/misinformation about COVID-19 vaccines to rebuild public confidence in vaccination. At the same time, Malawi has its own unique cultural and religious background, so it is essential to work with trusted community leaders. Religious leaders can also act as vaccine advocates, using existing trust relationships to advocate for vaccination [31,32].

Urban residents have more active vaccination behavior because it is more challenging to get vaccines for people who live in rural areas compared with urban areas. Thus, Malawi needs to improve access to vaccines for rural residents. We suggest targeted improvements in infrastructure, including logistics for vaccine transport and distribution [33,34], such as "MetaFridge", a portable ice tub for cryostorage and delivery. The preponderance of convenient vaccination sites should also be increased, especially in rural areas. International organizations and local governments should work together to cover the "last mile" of vaccination. This will also facilitate the establishment of long-term interventions and adaptive infrastructure that can be used for future disease control efforts.

We found that there are still gaps between COVID-19 vaccination intention and behavior. This suggests that real-world conditions may limit vaccination opportunities or that willing individuals may hesitate when vaccines become available. These issues should be addressed when planning vaccination campaigns. Last year, the Malawi government developed a new plan called the National COVID-19 Strategy and Plan—July 2021–June 2022 [35], which builds on the successes achieved and lessons learned from previous plans. The plan includes future control strategies for inter-cluster coordination, health, education, public communication, local governance, protection and social support, employment and labor force protection, transport and logistics, and security and enforcement. It focuses on moving from emergency to longer-term interventions and building from semi-permanent to permanent adaptive infrastructure. Our findings are consistent with ongoing strategies, particularly government-led advocacy, education, and infrastructure development.

This study has several limitations. Firstly, the results of this study may not represent the views or practices of the population as a whole. Secondly, given the cross-sectional nature of the data, the results represent a snapshot of vaccine indecision at one point in Vaccines 2022, 10, 760 11 of 21

time. We cannot explain how attitudes will evolve as the COVID-19 pandemic, vaccine availability, and political discourse change. Thirdly, there is an underlying social desirability bias, according to which participants may react in ways that they think are acceptable. Additionally, we did not assess the impact of rapid mutations of SARS-CoV-2 on COVID-19 vaccine uptake. For example, new mutant strains such as Delta and Omicron may re-infect people who have already been vaccinated with previous vaccines, which may negatively affect people's views on vaccination [36].

5. Conclusions

Overall, vaccine acceptance (including those who have been vaccinated and those who are willing to be vaccinated) was not high enough among the respondents to protect themselves and their communities. The health belief model structure can be used as a good predictor of vaccine acceptance, especially "perceived susceptibility", "perceived benefit", and "action cues". Strengthening COVID-19 vaccine education in these areas will be an essential future intervention.

Author Contributions: Conceptualization, H.Y. and Q.A.; methodology, Q.A.; formal analysis, Q.A.; data curation, R.O.E. and Q.A.; writing—original draft preparation, Q.A.; writing—review and editing, Q.A., R.O.E., H.Y. and F.C.; supervision, H.Y.; project administration, F.C.; funding acquisition, F.C. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the National Nature Science Foundation of China (No.72042014) and the "Double First-Class" Construction Program (BMU2020XY010).

Institutional Review Board Statement: The National Committee on Research in the Social Sciences and Humanities, The National Commission for Science and Technology approved this study (reference number: PROTOCOL P.08/21/593). Informed consent was acquired from the participants before the investigation started.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data generated during this study are included in this published article and Appendix A.

Acknowledgments: This report acknowledges the role of the enumerators in the data collection. We also thank the PKURTC team for supporting the research, and gratitude goes to Robert Egolet for leading the team throughout the fieldwork and report writing.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A. Data Collection Tools

English Questionnaire.

Table A1. COVID-19 vaccination acceptance questionnaire.

Interviewer ID:	Questionnaire ID:	Date:
Section A: Ge	eneral Information and Health Status	
1. Gender	1.1 1.2	Male Female
	2.1	18–24
	2.1	25–34
2. Year of Birth	2.3	35–44
	2.4 2.5	45–54 55 and above

Vaccines **2022**, *10*, *7*60 12 of 21

Table A1. Cont.

Interviewer ID:	Questionnaire ID:	Date:
Section A: General In	formation and Health Status	
3. Residence	3.1	Urban
	3.2	Rural
Indicate area of residence		
4 Polision	4.1 4.2	Christian Islam
4. Religion	4.3	Other
Other		
	5.1	Married
	5.2	Never married
5. Marital status	5.3	Divorced
	5.4	Widowed
	6.1	No high school
	6.2	High school
6. Education Attained	6.3	College
	6.4	Graduate/Professional
	6.5	Not educated
	7.1	Government employee
	7.2	Nongovernment employee
	7.3	Self-employed
7. Employment Status	7.4	Student
	7.5	Retired
	7.6	Unemployed
	7.7	Other (specify)
	8.1	Yes
	0.11	(If Yes)
	8.11	Physician,
8. Are you a healthcare worker?	8.12	Nurse,
•	8.13	Health Official,
	8.14	Researcher,
	8.15	Other
	8.2	No
	9.1	0–5000
9. What category (MWK) best fits your overall	9.2	5000-10,000
monthly income?	9.3	10,000–25,000
,	9.4	25,000–50,000
	9.5	50,000 and above
10. How many people live in your household (HH member	10.1	1–3
should have lived at household for at least six months or more)?	10.2 10.3	4–5 5 and above
of more).	10.0	
	11.1	We have electricity, and it functions at least half a day
	11.1	per day.
		per day. We have a safe, clean water
		source (piped into dwelling or
	11.2	
11. How would you describe your house's condition?		borehole with pump or protected dug well).
[check multiple answer option]		We have toilets in good
[encen manapre and wer op tron]	11.3	condition (flush or ventilated
	11.0	improved latrine).
		We are not crowded (5 or fewer
	11.4	people per room).
	44 =	We have a firm roo f(tiles or
	11.5	We have a firm roo f(tiles or galvanized iron or concrete).

Vaccines **2022**, 10, 760

Table A1. Cont.

Interviewer ID:	Questionnaire ID:	Date:
Section A: General I	nformation and Health Status	S
	12.1	Radio
	12.2	Television
	12.3	Stove
	12.4	Fridge
	12.5	Sofa
	12.6	Mobile phone
12. What does the household own as a family?	12.7	
	12.8	Bicycle Car
[check multiple answer option]		
	12.9	Motorbike
	12.10 12.11	oxcart Small livestock, e.g., poultry, goats, pigs
	12.12	Large livestock: cattle
	12.13	None
	12.14	other(specify)
13. Do you suffer from any chronic diseases?	13.1	Yes
	13.2	No
	14.1	Good
14. How would you perceive your overall health?	14.2	Fair
	14.3	Poor
15. Have you been (or are you currently) infected with	15.1	Yes
COVID-19?	15.2	No
16. Do you personally know someone who has been (or is	16.1	Yes
currently) infected with COVID-19?	16.2	No
17. Have you ever refused a vaccine recommended by a	17.1	Yes
	17.2	No
physician due to doubts you had about it?	17.2	Have never heard of any
	17.3	vaccine
Section 2: Perceived susceptibility,	severity and benefits of COV	VID-19 vaccine
18.Have you ever heard about a COVID-19 vaccine?	18.1	Yes
16.11ave you ever heard about a COVID-19 vaccine:	18.2	No
	19.1	Internet/TV
	19.2	Visits to healthcare providers
	19.3	Family members
	19.4	Radio
	19.5	School
19. Where do you obtain COVID-19 and vaccine	19.6	Church
information? [check multiple answer option]	19.7	Work place
	19.8	Friends
	19.9	Printed materials from
		healthcare providers
	19.10	Vaccine companies and industry
	19.11	Others(specify)
	20.1	Strongly agree
20. To what extent do you agree that COVID-19	20.2	Agree
is contagious?	20.3	Disagree
-	20.4	Strongly disagree
	21.1	Strongly agree
21. To what extent do you agree that the COVID-19	21.2	Agree
pandemic poses a risk to people in Malawi?	21.3	Disagree Strongly disagree

Vaccines **2022**, 10, 760

Table A1. Cont.

Interviewer ID:	Questionnaire ID:	Date:
Section A: General Ir	nformation and Health Status	5
	22.1	Strongly agree
22. Do you agree that the consequences of getting COVID-19	22.2	Agree
can be serious and can even lead to death?	22.3	Disagree
	22.4	Strongly disagree
	23.1	Strongly agree
23. Do you think getting COVID-19 is currently a possibility	23.2	Agree
for you?	23.3	Disagree
	23.4	Strongly disagree
24. Do you agree that a COVID 10 vaccine can degree the	24.1	Strongly agree
24. Do you agree that a COVID-19 vaccine can decrease the	24.2	Agree
chances of you contracting COVID-19 or suffering from	24.3	Disagree
its complications?	24.4	Strongly disagree
	25.1	Strongly agree
25. Do you agree that a COVID-19 vaccine can stop the virus	25.2	Agree
from spreading within communities and between countries?	25.3	Disagree
1 0	25.4	Strongly disagree
	26.1	Strongly agree
26. Do you agree that a COVID-19 vaccine should be	26.2	Agree
compulsory for all citizens and residents in Malawi?	26.3	Disagree
1 7	26.4	Strongly disagree
	27.1	Strongly agree
27. Do you agree that immunization requirements go	27.2	Agree
against freedom of choice?	27.3	Disagree
U	27.4	Strongly disagree
Section 3: Acceptability ar	nd Practice of a COVID-19 Va	nccine
28.a Have you been vaccinated with a COVID-19 vaccine?		Yes
20.a Have you been vacchated with a COVID 17 vacche.		No
	1–10	I was forced to do it.
		I want to travel outside.
		I got sick.
		Someone I knew died of
		COVID-19.
		Requirement for me to start job.
28.b Why did you choose to get vaccinated?		Peer pressure.
20.5 Trity and you choose to get vaccinated.		I was convinced by medical
		personnel.
		I want to protect myself from
		COVID
		I want to protect my family
		from COVID
		Other()
	28.1	I would accept immediately . [Go to Q31]
28.c Would you accept or refuse a COVID-19 vaccine when if it were available?	28.2	I would delay the vaccination. [Go to Q29]
2 1 e.e aranae.	28.3	I would refuse the vaccination. [Go to Q29]

Vaccines **2022**, *10*, *7*60 15 of 21

Table A1. Cont.

Interviewer ID:	Questionnaire ID:	Date:
Section A: General 1	nformation and Health Status	
	29.1	I don't believe in the existence of COVID-19.
	29.2	I think the vaccine is a plot.
	29.3	I am religious and God will
	2,10	protect me.
	29.4	COVID-19 symptoms are mostly mild so I do not fear COVID-19.
	29.5	I feel that masks and sanitizers are sufficient for protection.
	29.6	I think the vaccine will transmit the virus to me.
	29.7	I think the vaccine will change my genes.
	29.8	I don't think that I can afford the vaccine.
29. I would delay or refuse the vaccination because-[check multiple answer option]	29.9	The fear of adverse side effects. Not convinced that it will be
	29.10	effective.
	29.11	Concern regarding the faulty/fake COVID-19 vaccines.
	29.12	The speed of developing the vaccine was too fast.
	29.13	The short duration of clinical trials.
	29.14	There is no way I trust governments.
	29.15	Illness or allergy prevented me from getting vaccinated.
		I feel the COVID vaccine is
	16	associated with other religious
	17	hidden agendas. Others()
	30.1	I were given adequate information about it.
	30.2	The vaccine were taken by many people.
	30.3	The vaccine's safety were confirmed.
30. I would take the COVID-19 vaccine only if- [check	30.4	The vaccine were provided for
multiple answer option]	30.5	free. The doctor advised me to get
	30.6	vaccinated. The government required me to
		get vaccinated. The WHO or UNICEF staff
	30.7	provided me with a vaccine.
	30.8 30.9	No vaccinations at all. Other
31 How much are you willing to pay for COVID-19 vaccines?	M	WK
	about and trust the following vaccir	nes?
Manufacture I don't know at all	I've heard of it but I don't trust	I know about it and I trust it

Vaccines 2022, 10, 760 16 of 21

Table A1. Cont.

Interviewer ID: _	Questionnaire ID:	Date:		
Section A: General Information and Health Status				
AstraZeneca/Oxford vaccine [UK]				
Johnson and Johnson [US]				
Moderna [US]				
NOVAVAX [US]				
Janssen [US]				
Pfizer/BionTech [China]				
Sinovac [China]				
IMBCAMS [China]				
Zhifei Longcom [China]				
Sinopharm Beijing [China]				
CanSinoBIO [China]				
THE GA Vector State Research Centre of Viralogy and Biotechnology [Russia]				
MALEYA NATIONAL CENTER [Russia]				
Serum Institute [India]				

Chichewa Translated COVID-19 Vaccination Acceptance Questionnaire. Mafunso wokhudza Kuvomereza Katemera wa COVID-19. Malonje.

Dzina langa ndine______ ndachokela ku _____ amene tikupanga zakafukufuku pa zomwe mumadziwa pankhani ya Katemera wa COVID-19. Zokambilana zathu zikhala muzigawo ziwiri zotele: gawo la Zokhudza muthu ndi umoyo wake; ndi gawo la Maganizo pakukhudziwa, Muyenso komanso kufunika kwa Katemera wa COVID-19.

Macheza athu atenga pafupifupi mpindi nkhumi ndi zisanu ndipo zonse zimene tikhale tikukambilana zikhala zachinsinsi. Kutengapo mbali kwanu mukafukufuku ameneyu ndikosakakamiza ndipo mukhoza kukana kutenga nawo mbali kapena kusiila panjira macheza amenewa. Ngati mwasankha kuti simutenga nawo mbali pakafukufuku ameneyu simulandila chilango chilichonse kapena kulandidwa Katundu aliyense. Chizindikiilo chanu cha mzika chingowilitsidwa ntchito pakungoonetsa kuti inuyo munavomeleza kuchita nawo kafukufuku ameneyu, koma sichidzagwilitsadwanso ntchito penapaliponse.

Mukuvomeleza kutenga nawo mbali pakafukufuku ameneyi? Inde Ayi.

Table A2. Mafunso wokhudza Kuvomereza Katemera wa COVID-19. Malonje.

ID ya Ofunsa Mafunso:	Questionnaire ID:	Tsiku:
Gawo 1: Zokhudza Muthu Ndi Umoyo Wake		
1 M /M:	1.1	Mamuna
1. Mamuna/Mkazi	1.2	Mkazi

Vaccines **2022**, *10*, *7*60 17 of 21

Table A2. Cont.

ID ya Ofunsa Mafunso:	Questionnaire ID:	Tsiku:
Gawo 1: Zokhudza Mu	thu Ndi Umoyo Wake	
	2.1	18–24
	2.2	25–34
2. Muli ndi zaka zingati?	2.3	35–44
	2.4	45–54
	2.5	55 kupita mtsogolo
2 D 1 1 1 1	3.1	Mtawuni
3. Dela lokhala	3.2	Kumudzi
	4.1	Chikhilisitu
4. Ndinu achipembedzo chanji?	4.2	Chisilamu
in i tumu ucrup cinic cuzo crumiji.	4.3	Zina (Tchulani)
	5.1	Ndili pa banja
5. Muli pa banja?	5.2 5.2	Sinnakwatirepo
• ,	5.3 5.4	Banja linatha
	3.4	Wa masiye
	6.1	Sanafike sekondale
6. Maphuzilo anu munalekezera pati?	6.2	Sekondale
or map ment mu manuferezetu putt.	6.3	Kunapita ku Koleji
	6.4	Anaphunzira ku
		university
	7.1	Amagwira ntchito mu
		boma
	7.2	Amagwira ntchito
7. Mumagwira ntchito yanji?	7 .0	kumabugwe
7. Managwila iterito yangi.	7.3	Anazilemba okha ntchito
	7.4	Mwana wasukulu
	7.5	Anapanga litaya
	7.6	Sali pa ntchito
	7.7	Zina (Tchulani)
	8.1	Eya (ngati eya)
	8.11	Owona odwala
	0.11	(Physicians),
8. Kodi ndinu ogwira ntchito za umoyo (zachipatala)?	8.12	Nurses,
or riour name og one memo za amo y o (zaempanam).	8.13	Oyang'anira za umoyo
	0.13	(Health Officials),
	8.14	Opanga zakafukufuku
	8.14	(Researchers),
	8.15	Zina (Others)
	8.2	Ayi
	9.1	0–5000
	9.2	5000–10,000
9. Mumapeza ndalama zingati pa mwezi??	9.3	10,000–25,000
	9.4	25,000–50,000
	9.5	50,000 kupita mtsogolo
10 Palhamananan 11 1 and an evolution 11		
10. Pakhomo pano pamakhala anthu angati (Okhala pakhomo	10.1	1–3 4–5
akhale amene wakhala pabanjapo posachepera miyezi isanu ndi umodzi)?	10.2 10.3	
nar amouzij:	10.3	5 kupita mtsogolo
		Tili ndi magetsi, atha
	11.1	kukhala akuyaka
	11.1	mafupifupi theka la tsiku,
		tsiku lililonse.
11. Kodi nyumba yanu mungayifotokoze bwanji? [Mayankho		Tili ndi kochokera madzi
ambiri ndi ololedwa]		awukhondo (Madzi a
umbin nui oloicumuj	11.2	muma paipi, Mijigo
		kapena zitsime
		zotetezedwa)
		Tili ndi zimbudzi za
		ukhondo komanso
	11.3	zabwino (Zo flasha

Vaccines **2022**, 10, 760 18 of 21

Table A2. Cont.

ID ya Ofunsa Mafunso:		Questionnaire ID:	Tsiku:	
	Gawo 1: Zokhudza Muth	u Ndi Umoyo Wake		
		11.4	Sitili odzadzana (Timakhala athu ochepera 5 (asanu) mu chipinda).	
		11.5	Tili ndi denga lolimba (tiles or malata kapena concrete).	
		12.1	Radio	
		12.2	Television	
		12.3	Stove	
		12.4	Fridge	
12. Kodi Pakhomo pano, muli ndi zir	nthu ziti ngati banja?	12.5	Sofa	
[Mayankho ambiri ndi o		12.6	Mobile phone	
- ,	_	12.7	Njinga	
		12.8	Galimoto	
		12.9	Njinga yamoto	
		12.10	Ngolo	
		12.11	Zina (Tchulani)	
12 M 1 1		13.1	Yes	
13. Mumadwala matenda a 1	mgonagona?	13.2	Ayi	
		14.1	Uli bwino	
14. Mukuona ngati umoyo wa	nu uli bwanji?	14.2	Uli pakatikati	
Ç	,	14.3	Suli bwino	
		15.1	Eya	
15. Kodi munapezekako kapena padali p	ano muli ndi COVID-19?	15.2	Ayi	
16. Mukudziwako wina wake amene	e anali kapena ali ndi	16.1	Eya	
COVID-19, mbanja mwanu kapen		16.2	Ayi	
17. Kodi munakanako katemera chifukwa chakumukayikira?		17.1 17.2	Eya Ayi	
Gawo 2: Maganizo pakı	ıkhudziwa, Muyenso kom	anso kufunika kwa Katem	· · · · · · · · · · · · · · · · · · ·	
18. Munamvako zaketemera wa 18.1			Eya	
COVID-19?	18.2	Ayi		
	19.1	Int	aneti/TV	
	19.2		o othandizira odwala	
	19.3		nja ndi azibale	
19. Kodi mauthenga okhudza	19.4		Ázanga	
COVID-19 ndi katemera	19.5	Zolemba kapena ma po	ster opangidwa ndi achipatala	
mungaupeze kuti?	19.6	Ma Kampan	ii opanga katemera	
[Mayankho ambiri ndi	19.7	Wayilesi		
ololedwa]	19.8	Ku sukulu		
	19.9		Kuntchito	
	19.91		Tchalitchi	
	19.92	Zina	Zina (Tchulani)	
20. Kodi mukugwirizana nazo	20.1		ana nazo kwambiri	
bwanji kuti matenda a COVID-19	20.2		wilizana nazo	
ndiopatsirana?	20.3		gwilizana nazo	
01 K 1: 1	20.4		ilizana nazo konse	
21. Kodi mukugwirizana nazo 21.1		Ndikugwilizana nazo kwambiri		
bwanji kuti matenda a COVID 19 21.2 ayika pachiopsezo anthu 21.3		Ndikugwilizana nazo		
		Sindikugwilizana nazo		
(mtundu wa) aku Malawi?	21.4	Sindikugwilizana nazo konse		
22. Mukugwirizana nazo bwanji	22.1		ana nazo kwambiri	
kuti zotsatira za matenda a	22.2	Ndikugwilizana nazo		
COVID-19 atha kukhala oopsa	22.3		gwilizana nazo	
mpaka munthu kumwalira?	22.4	Sinaikugwi	ilizana nazo konse	

Vaccines **2022**, 10, 760

Table A2. Cont.

ID ya Ofunsa Mafunso:		Questionnaire ID: Tsiku:		
Gawo 1: Zokhudza Muthu Ndi Umoyo Wake				
22 Malasana marki madaki mana	23.1	Ndikugwilizana nazo kwambiri		
23. Mukuona ngati padali pano,	23.2	Ndikugwilizana nazo		
ndizotheka kutenga matenda a	23.3	Sindikugwilizana nazo		
COVID-19?	23.4	Sindikugwilizana nazo konse		
24. Mukugwirizana zano bwanji kuti	24.1	Ndikugwilizana nazo kwambiri		
katemera wa COVID 19 atha	24.2	Ndikugwilizana nazo		
kuchepetsa kuthekera kotenga matenda	24.3	Sindikugwilizana nazo		
a COVID-19 kapena zotsatira zake?	24.4	Sindikugwilizana nazo konse		
25. Mukugwirizana nazo bwanji kuti	25.1	Ndikugwilizana nazo kwambiri		
katemera wa COVID-19 atha kuletsa	25.2	Ndikugwilizana nazo		
(kusiyiza) kufalikira kwa matendawa	25.3	Sindikugwilizana nazo		
mu mmadera amayiko?	25.4	Sindikugwilizana nazo konse		
26. Kodi mukugwirizana nazo bwanji	26.1	Ndikugwilizana nazo kwambiri		
kuti Katemera wa COVID-19 azikhala	26.2	Ndikugwilizana nazo		
wokakamiza kwa nzika zonse ndi	26.3	Sindikugwilizana nazo		
okhala mdziko muno?	26.4	Sindikugwilizana nazo konse		
27 M. L	27.1	Ndikugwilizana nazo kwambiri		
27. Mukugwirizana nazo bwanji	27.2	Ndikugwilizana nazo		
ndizakuti zofunika poziteteza	27.3	Sindikugwilizana nazo		
zimatsutsana ndi ufulu wachisankho?	27.4	Sindikugwilizana nazo konse		
Gawo 3: Kuvome	reza komanso z	ochita kukhudza katemera wa COVID-19		
00 W. P	28.1	Nditha kulora pompo pompo. [pitan ku Q31]		
28. Kodi mutha kulola kapena kukana	28.2	Nditha kuchedwa kuvomera [pitan ku Q29]		
katemera wa COVID-19, atapezeka ?	28.3	Nditha kukana katemerayi. [pitan ku Q29]		
	29.1	Sindikhulupilira kutI COVID-19 ilipo.		
	29.2	I think the vaccine is a plot.		
	29.3	Ndine wachipembedzo, mulungu anditeteza.		
	29.4	Zizindikiro za matenda a COVID-19 amakhala osaopsa		
	29.5	kwenikweni, sindiopa za COVID-19.		
		Ndimaona ngati masiki ndi hand sanitizer ndizokwanira		
29. Nditha kuchedwa kuvomera ka	_,	kunditeteza ku matendawa.		
kukana katemerayi, chifukwa:	29.6	Ndikuona ngati katemera atha kundipatsira matenda a		
[Mayankho ambiri ndi ololedwa]	29.7	COVID-19. Ndikuona ngati katemera atha kusintha ma genes anga		
	• • •			
	29.8 29.9	Sindingakwanitse kulipira katemerayu. Ndimaopa zotsatira zoopsa za katemerayi.		
	29.10	Sindine okhutitsidwa kuti katemerayu atha kugwira ntchito		
	29.10	Ndimaopa kuti katemera wina atha kukhala wa fake.		
	29.11			
		Ndikuona ngati katemerayu wapangidwa mwachangu.		
	29.13	Katemerayu sanayezedwe mokwanira.		
	29.14	Boma sindilikhulupilira.		
	29.15	Matenda kapena zowenga zinandiletsa kusabayitsa katemerayi.		
	30.1	Ndapatsidwa uphungu ndi uthenga okwanira.		
	30.2	Katemera akubayitsidwa ndi athu ambiri.		
	30.3	Chitetezo cha katemerayi ndichosakayikitsa/chostimikizidwa.		
30. Nditha kukabayitsa katemera wa	30.4	Katemera atakhala waulere.		
COVID-19, pokhapokha: [Mayankho	30.5	Adotolo andilangiza kukabayitsa katemera.		
ambiri ndi ololedwa]	30.6	Malamulo a bowa akundiyenera kuti ndibayitse katemera.		
	30.7	Mabugwe a WHO kapena UNICEF ndiamene akubaya		
		katemerayu.		
	30.8	Palibe katemerayu ndikomwe.		
	30.9	Zina (Tchulani)		

Vaccines 2022, 10, 760 20 of 21

Table A2. Cont.

ID ya Ofunsa Mafur	180:	Questionnaire ID:	Tsiku:	
	Gawo 1: Zokhudza Muthu Ndi Umoyo Wake			
31. Mutha kulipira ndalama zingati, kutakhala kuti katemera wa COVID-19 yu ndiwolipilitsa?				
		MK		
32. Mun	nadziwa bwanji ndi kukhulup	ilira mitundu yamakatemera aw	va?	
Opanga	Sindidziwa kathu	Nnamvako koma sindimukhulupilira	Ndikumudziwa komanso ndimamukhulupirira	
AstraZeneca/Oxford vaccine [UK]				
Johnson and Johnson [US]				
Moderna [US]				
NOVAVAX [US]				
Janssen [US]				
Pfizer/BionTech [China]				
Sinovac [China]				
IMBCAMS [China]				
Zhifei Longcom, [China]				
Sinopharm Beijing [China]				
CanSinoBIO [China]				
THE GA Vector State Research Centre of Viralogy and Biotechnology [Russia]				
MALEYA NATIONAL CENTER [Russia]				
Serum Institute [India]				

References

- 1. Adigwe, O.P. COVID-19 vaccine hesitancy and willingness to pay: Emergent factors from a cross-sectional study in Nigeria. *Vaccine X* **2021**, *9*, 100112. [CrossRef] [PubMed]
- Alobaidi, S. Predictors of Intent to Receive the COVID-19 Vaccination Among the Population in the Kingdom of Saudi Arabia: A Survey Study. J. Multidiscip. Healthc. 2021, 14, 1119–1128. [CrossRef] [PubMed]
- 3. Li, Y.; Liu, G.; Egolet, R.; Yang, R.; Huang, Y.; Zheng, Z. Knowledge, Attitudes, and Practices Related to COVID-19 Among Malawi Adults: A Community-Based Survey. *Int. J. Environ. Res. Public Health* **2021**, *18*, 4090. [CrossRef] [PubMed]
- 4. Biswas, R.; Alzubaidi, M.S.; Shah, U.; Abd-Alrazaq, A.A.; Shah, Z. A Scoping Review to Find Out Worldwide COVID-19 Vaccine Hesitancy and Its Underlying Determinants. *Vaccines* **2021**, *9*, 1243. [CrossRef]
- 5. Perceived Public Health Threat a Key Factor for Willingness to Get the COVID-19 Vaccine in Australia. Available online: https://pubmed.ncbi.nlm.nih.gov/34391594/ (accessed on 11 April 2022).
- Mondal, P.; Sinharoy, A.; Su, L. Sociodemographic predictors of COVID-19 vaccine acceptance: A nationwide US-based survey study. Public Health 2021, 198, 252–259. [CrossRef]
- 7. Okubo, R.; Yoshioka, T.; Ohfuji, S.; Matsuo, T.; Tabuchi, T. COVID-19 Vaccine Hesitancy and Its Associated Factors in Japan. *Vaccines* **2021**, *9*, 662. [CrossRef]
- 8. Reiter, P.L.; Pennell, M.L.; Katz, M.L. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? *Vaccine* **2020**, *38*, 6500–6507. [CrossRef]
- 9. Rhodes, A.; Hoq, M.; Measey, M.-A.; Danchin, M. Intention to vaccinate against COVID-19 in Australia. *Lancet Infect. Dis.* **2020**, 21, e110. [CrossRef]
- COVID-19 Vaccination Intention in the UK: Results from the COVID-19 Vaccination Acceptability study (CoVAccS), a Nationally Representative Cross-Sectional Survey. Available online: https://pubmed.ncbi.nlm.nih.gov/33242386/ (accessed on 11 April 2022).

Vaccines 2022, 10, 760 21 of 21

11. Paul, E.; Steptoe, A.; Fancourt, D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. *Lancet Reg. Health Eur.* **2021**, *1*, 100012. [CrossRef]

- 12. Qattan, A.M.N.; Alshareef, N.; Alsharqi, O.; Al Rahahleh, N.; Chirwa, G.C.; Al-Hanawi, M.K. Acceptability of a COVID-19 Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. *Front. Med.* **2021**, *8*, 644300. [CrossRef]
- 13. Khalafalla, H.E.; Tumambeng, M.Z.; Halawi, M.H.A.; Masmali, E.M.A.; Tashari, T.B.M.; Arishi, F.H.A.; Shadad, R.H.M.; Alfaraj, S.Z.A.; Fathi, S.M.A.; Mahfouz, M.S. COVID-19 Vaccine Hesitancy Prevalence and Predictors among the Students of Jazan University, Saudi Arabia Using the Health Belief Model: A Cross-Sectional Study. *Vaccines* 2022, 10, 289. [CrossRef]
- 14. Factors Associated with COVID-19 Vaccine Hesitancy after Implementation of a Mass Vaccination Campaign. Available online: https://pubmed.ncbi.nlm.nih.gov/35214739/ (accessed on 11 April 2022).
- 15. Badr, H.; Zhang, X.; Oluyomi, A.; Woodard, L.D.; Adepoju, O.E.; Raza, S.A.; Amos, C.I. Overcoming COVID-19 Vaccine Hesitancy: Insights from an Online Population-Based Survey in the United States. *Vaccines* **2021**, *9*, 1100. [CrossRef]
- 16. Health Belief Model Perspective on the Control of COVID-19 Vaccine Hesitancy and the Promotion of Vaccination in China: Web-Based Cross-sectional Study. Available online: https://pubmed.ncbi.nlm.nih.gov/34280115/ (accessed on 11 April 2022).
- 17. Mahmud, I.; Kabir, R.; Rahman, M.; Alradie-Mohamed, A.; Vinnakota, D.; Al-Mohaimeed, A. The Health Belief Model Predicts Intention to Receive the COVID-19 Vaccine in Saudi Arabia: Results from a Cross-Sectional Survey. *Vaccines* **2021**, *9*, 864. [CrossRef]
- 18. Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study. Available online: https://pubmed.ncbi.nlm.nih.gov/35062750/ (accessed on 11 April 2022).
- Williams, L.; Gallant, A.J.; Rasmussen, S.; Nicholls, L.A.B.; Cogan, N.; Deakin, K.; Young, D.; Flowers, P. Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: Outlining evidence-based and theoretically informed future intervention content. Br. J. Health Psychol. 2020, 25, 1039–1054. [CrossRef]
- 20. Moucheraud, C.; Phiri, K.; Whitehead, H.S.; Songo, J.; Lungu, E.; Chikuse, E.; Phiri, S.; van Oosterhout, J.J.; Hoffman, R.M. Uptake of the COVID-19 vaccine among healthcare workers in Malawi. *Int. Health* 2022, ihac007. [CrossRef]
- 21. Otiti-Sengeri, J.; Andrew, O.B.; Lusobya, R.C.; Atukunda, I.; Nalukenge, C.; Kalinaki, A.; Mukisa, J.; Nakanjako, D.; Colebunders, R. High COVID-19 Vaccine Acceptance among Eye Healthcare Workers in Uganda. *Vaccines* **2022**, *10*, 609. [CrossRef]
- 22. Cai, Z.; Hu, W.; Zheng, S.; Wen, X.; Wu, K. Cognition and Behavior of COVID-19 Vaccination Based on the Health Belief Model: A Cross-Sectional Study. *Vaccines* **2022**, *10*, 544. [CrossRef]
- 23. Acceptance of the COVID-19 Vaccine Based on the Health Belief Model: A Population-Based Survey in Hong Kong. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832076/ (accessed on 4 May 2022).
- 24. Scognamiglio, F.; Gori, D.; Montalti, M. Vaccine Hesitancy: Lessons Learned and Perspectives for a Post-Pandemic Tomorrow. *Vaccines* **2022**, *10*, 551. [CrossRef]
- 25. COVID-19 Vaccine Hesitancy and Determinants of Acceptance among Healthcare Workers, Academics and Tertiary Students in Nigeria. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032510/ (accessed on 4 May 2022).
- 26. Al-Mansour, K.; Alyahya, S.; AbuGazalah, F.; Alabdulkareem, K. Factors Affecting COVID-19 Vaccination among the General Population in Saudi Arabia. *Healthcare* **2021**, *9*, 1218. [CrossRef]
- 27. Tran, V.D.; Pak, T.V.; Gribkova, E.I.; Galkina, G.A.; Loskutova, E.E.; Dorofeeva, V.V.; Dewey, R.S.; Nguyen, K.T.; Pham, D.T. Determinants of COVID-19 vaccine acceptance in a high infection-rate country: A cross-sectional study in Russia. *Pharm. Pract.* (*Granada*) 2021, 19, 2276. [CrossRef]
- 28. Li, X.-H.; Chen, L.; Pan, Q.-N.; Liu, J.; Zhang, X.; Yi, J.-J.; Chen, C.-M.; Luo, Q.-H.; Tao, P.-Y.; Pan, X.; et al. Vaccination status, acceptance, and knowledge toward a COVID-19 vaccine among healthcare workers: A cross-sectional survey in China. *Hum. Vaccines Immunother.* **2021**, *17*, 4065–4073. [CrossRef]
- 29. Patwary, M.M.; Alam, A.; Bardhan, M.; Disha, A.S.; Haque, Z.; Billah, S.M.; Kabir, P.; Browning, M.H.E.M.; Rahman, M.; Parsa, A.D.; et al. COVID-19 Vaccine Acceptance among Low- and Lower-Middle-Income Countries: A Rapid Systematic Review and Meta-Analysis. *Vaccines* 2022, 10, 427. [CrossRef]
- 30. Kanyanda, S.; Markhof, Y.; Wollburg, P.; Zezza, A. Acceptance of COVID-19 vaccines in sub-Saharan Africa: Evidence from six national phone surveys. *BMJ Open* **2021**, *11*, e055159. [CrossRef]
- 31. Moola, S.; Gudi, N.; Nambiar, D.; Dumka, N.; Ahmed, T.; Sonawane, I.R.; Kotwal, A. A rapid review of evidence on the determinants of and strategies for COVID-19 vaccine acceptance in low- and middle-income countries. *J. Glob. Health* **2021**, 11, 05027. [CrossRef]
- 32. Davis, T.P.; Yimam, A.K.; Kalam, A.; Tolossa, A.D.; Kanwagi, R.; Bauler, S.; Kulathungam, L.; Larson, H. Behavioural Determinants of COVID-19-Vaccine Acceptance in Rural Areas of Six Lower- and Middle-Income Countries. *Vaccines* **2022**, *10*, 214. [CrossRef]
- 33. Sun, J.; Zhang, M.; Gehl, A.; Fricke, B.; Nawaz, K.; Gluesenkamp, K.; Shen, B.; Munk, J.; Hagerman, J.; Lapsa, M.; et al. Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution. *Sci. Data* 2022, *9*, 67. [CrossRef] [PubMed]
- 34. Management of COVID-19 Vaccines Cold Chain Logistics: A Scoping Review. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889047/ (accessed on 4 May 2022).
- 35. National COVID-19 Preparedness and Response Strategy and Plan: July 2021- June 2022. Available online: https://malawi.un.org/en/138774-national-covid-19-preparedness-and-response-strategy-and-plan-july-2021-june-2022 (accessed on 5 August 2021).
- 36. Booster COVID-19 Vaccination Against the SARS-CoV-2 Omicron Variant: A Systematic Review. Available online: https://pubmed.ncbi.nlm.nih.gov/35499517/ (accessed on 4 May 2022).